Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Completed · Phase 2 · Has a placebo group
Conditions studied: Glabellar Frown Lines
In brief
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
Key facts
- Study ID
- NCT03736928
- Run by
- Galderma R&D
- People needed
- 401
- Starts
- 2018-11-26
- Expected to finish
- 2020-08-20
- Last updated by the study team
- 2022-08-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Moderate to severe glabellar lines at maximum frown as assessed by the Investigator using a photographic scale
- Moderate to severe glabellar lines at maximum frown as assessed by the subject using a static categorical scale
You may not qualify if…
- Botulinum toxin treatment in the face within 9 months prior to study treatment
Where it is running
- Galderma Research Site — Encino, California, United States
- Galderma Research Site — Manhattan Beach, California, United States
- Galderma Research Site — Vista, California, United States
- Galderma Research Site — Coral Gables, Florida, United States
- Galderma Research Site — Chicago, Illinois, United States
- Galderma Research Site — New Orleans, Louisiana, United States
- Galderma Research Site — New York, New York, United States
- Galderma Research Site — Chapel Hill, North Carolina, United States
- Galderma Research Site — Charlotte, North Carolina, United States
- Galderma Research Site — Mequon, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.